These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26033401)

  • 1. MET in gastric cancer--discarding a 10% cutoff rule.
    Metzger ML; Behrens HM; Böger C; Haag J; Krüger S; Röcken C
    Histopathology; 2016 Jan; 68(2):241-53. PubMed ID: 26033401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
    Catenacci DV; Ang A; Liao WL; Shen J; O'Day E; Loberg RD; Cecchi F; Hembrough T; Ruzzo A; Graziano F
    Cancer; 2017 May; 123(6):1061-1070. PubMed ID: 27926778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm.
    Park CK; Park JS; Kim HS; Rha SY; Hyung WJ; Cheong JH; Noh SH; Lee SK; Lee YC; Huh YM; Kim H
    Oncotarget; 2016 Nov; 7(44):72099-72112. PubMed ID: 27765925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy.
    An X; Wang F; Shao Q; Wang FH; Wang ZQ; Wang ZQ; Chen C; Li C; Luo HY; Zhang DS; Xu RH; Li YH
    Cancer; 2014 Mar; 120(5):675-82. PubMed ID: 24804300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of Amplification and Expression of the C-MYC Gene with Survival among Gastric Cancer Patients.
    Khaleghian M; Shakoori A; Razavi AE; Azimi C
    Asian Pac J Cancer Prev; 2015; 16(16):7061-9. PubMed ID: 26514491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.
    Zhang J; Guo L; Liu X; Li W; Ying J
    Oncotarget; 2017 Feb; 8(6):10264-10273. PubMed ID: 28052014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of MET mRNA in gastric cancer in situ. Comparison with immunohistochemistry and sandwich immunoassays.
    Schmid E; Klotz M; Steiner-Hahn K; Konen T; Frisk AL; Schatz C; Krahn T; von Ahsen O
    Biotech Histochem; 2017; 92(6):425-435. PubMed ID: 28836864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
    Mignard X; Ruppert AM; Antoine M; Vasseur J; Girard N; Mazières J; Moro-Sibilot D; Fallet V; Rabbe N; Thivolet-Bejui F; Rouquette I; Lantuejoul S; Cortot A; Saffroy R; Cadranel J; Lemoine A; Wislez M
    J Thorac Oncol; 2018 Dec; 13(12):1962-1967. PubMed ID: 30149144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1.
    Yang Y; Wang C; Dai C; Liu X; Li W; Huang M; Zhao X; Ji D; Li J; Guo W
    Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):547-557. PubMed ID: 33693450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
    Das K; Gunasegaran B; Tan IB; Deng N; Lim KH; Tan P
    Cancer Lett; 2014 Oct; 353(2):167-75. PubMed ID: 25086186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers.
    Kwon MJ; Kim JW; Jeon JY; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Min KW; Choe JY; Lee HK
    Pathol Res Pract; 2017 Apr; 213(4):381-388. PubMed ID: 28214200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization.
    Choi J; Lee HE; Kim MA; Jang BG; Lee HS; Kim WH
    PLoS One; 2014; 9(11):e111658. PubMed ID: 25364819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET expression and amplification in patients with localized gastric cancer.
    Janjigian YY; Tang LH; Coit DG; Kelsen DP; Francone TD; Weiser MR; Jhanwar SC; Shah MA
    Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):1021-7. PubMed ID: 21393565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.
    Peng Z; Li Z; Gao J; Lu M; Gong J; Tang ET; Oliner KS; Hei YJ; Zhou H; Shen L
    Mol Cancer Ther; 2015 Nov; 14(11):2634-41. PubMed ID: 26330547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.
    Kim HS; Chon HJ; Kim H; Shin SJ; Wacheck V; Gruver AM; Kim JS; Rha SY; Chung HC
    J Surg Oncol; 2018 Jun; 117(8):1679-1686. PubMed ID: 29790169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNK2 gene amplification is a novel predictor of a poor prognosis in patients with gastric cancer.
    Shinmura K; Kiyose S; Nagura K; Igarashi H; Inoue Y; Nakamura S; Maeda M; Baba M; Konno H; Sugimura H
    J Surg Oncol; 2014 Mar; 109(3):189-97. PubMed ID: 24178904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray.
    Rakhshani N; Kalantari E; Bakhti H; Sohrabi MR; Mehrazma M
    Asian Pac J Cancer Prev; 2014; 15(18):7597-602. PubMed ID: 25292034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
    Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
    Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.